Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Brighter AB (publ) ("Brighter" or the "Company") today announces the outcome of the exercise of warrants of series TO7, which were issued during the first quarter of 2022. In total, 149,880,263 warrants of series TO7 were exercised, corresponding to approximately 45.0 percent of the total number of outstanding warrants of series TO7, for subscription of 149,880,263 shares at a subscription price of SEK 0.078 per share. Brighter will receive approximately SEK 11.7 million before issuing costs through the exercise of the warrants of series TO7.
Background
The subscription period for exercise of the warrants of series TO7 took place from June 1, 2022, up to and including June 15, 2022. The subscription price per share for exercising the warrants of series TO7 was set to SEK 0.078.
In total, 149,880,263 warrants of series TO7 were exercised for subscription of 149,880,263 shares, meaning that approximately 45.0 percent of all outstanding warrants of series TO7 were exercised for subscription of shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital, and dilution
Through the exercise of the warrants of series TO7, the number of shares in Brighter increases by 149,880,263 shares, from 723,644,682 to a total of 873,524,945 shares. The share capital increases by SEK 7,494,013.15 from SEK 36,182,234.10 to SEK 43,676,247.25.
For existing shareholders who did not exercise any warrants of series TO7, the dilution amounts to approximately 17.2 percent of the number of shares and votes in the Company.
Advisor
Mangold Fondkommission AB is the financial advisor to the Company regarding the warrants.
For more information, please contact:
Investor Relations
IR@brighter.se
Certified Adviser
Brighter's Certified Adviser is Mangold Fondkommission AB,
+46 8 52 77 5020, ca@mangold.se,www.mangold.se
About Brighter
Brighter is a health-tech Company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers - aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO13485 certified. In 2019 the Company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at www.brighter.se
This information is such that Brighter AB (publ) is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on June 17, 2022, at 07:30 CET.